Are you a financial expert?Login
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Signup

STAR

410.05
-2.35 (-0.57%)
Updated 03:29 07/07 IST

STAR Buy or Sell - FrontPage Forums

1 Users have submitted 1 trade ideas of Rs. 21,800 for STAR
Disclaimer
100% Bullish
0% Bearish

STAR Buy or Sell - Brokerage Reports

No. of reports in last year
2
No. of analysts
2
Average Consensus Forecast
398.5
Consensus Potential
-4.62%
See STAR Share Price Targets >>

STAR Ratings

Long term STAR rating by FrontPage users
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
5/5 (2 Ratings)
Find answers to all your questions on live STAR message board: Is STAR buy or sell? Should I buy STAR shares? Why are STAR shares falling? Should I invest in STAR stock?

  1. Home
  2. STAR Forum

STAR Share Price Discussion

C
Commoditynivesh @commoditynivesh
Reputation: 423 • Jul 1 5:28 AM
Type
Buy
Instrument
STAR
Entry Price
₹411
Price@Trade
₹406.7
Target Price
₹414.1
Stop Price
₹407.9
Valid Till
Jul 1, 2020 3:20 AM
Margin
₹411,000 approx for 1000 Qty
Status
Waiting for entry
#STAR
Like
Reply
T
TradeAdda @nishantshah91
Reputation: 10,644 • Jun 25 3:20 AM
Type
Buy
Instrument
STAR
Entry Price
₹434
Price@Trade
₹434.25
Target Price
₹460
Stop Price
₹419
Valid Till
Jul 24, 2020 3:20 AM
Margin
₹43,400 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹419
Net P&L
-₹1,500 (-3.46%)
#STAR
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
•
Jun 25 3:22 AM
Update
Trade Entered
Entry Price
₹434
TrackerBot @trackerbot
•
Jun 29 3:51 AM
Update
Stoploss Hit
Exit Price
₹419
N
NewsBot @newsbot
Reputation: 3,757 • Jun 23 3:23 AM
Promoter Participaciones acquires 1.38% stake in Mahindra CIE, Lifecell offloads 1.07% in Strides Pharma
Beacon Trusteeship sold 5,57,271 shares (representing 0.69 percent of total paid up equity capital) in Tourism Finance Corporation at Rs 37.65 per share
Moneycontrol
Like
Reply
B
Billion Club @100billionclub
Reputation: 5,138 • Jun 23 4:17 AM
Type
Buy
Instrument
STAR
Entry Price
₹436
Price@Trade
₹444
Target Price
₹520
Stop Price
₹399
Valid Till
Jul 23, 2020 3:20 AM
Margin
₹21,800 approx for 50 Qty
Status
Active
#STAR
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
•
Jun 24 3:55 AM
Update
Trade Entered
Entry Price
₹436
N
NewsBot @newsbot
Reputation: 3,757 • Jun 19 11:26 AM
China to revamp benchmark equity index, STAR as pursues growth
Red-chip stocks are those incorporated outside mainland China but listed on Chinese bourses.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • Jun 19 9:18 AM
COVID-19 treatment | Indian companies begin exports of Favipiravir, but wait for approval in India
Sources told Moneycontrol that Glenmark's Favipiravir is expected to get approval from drug regulator any moment, based on the intermediate data from the clinical trials given the urgency of the situation
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • Jun 5 6:31 AM
Sun Pharma testing plant-based drug as potential COVID-19 treatment
Drugmakers around the world are rushing to develop a treatment or vaccine for the fast-spreading novel coronavirus that has killed over 390,000 people and ravaged financial markets. Two other Indian companies, Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd, are also conducting trials in India for potential COVID-19 treatments.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • Jun 2 7:23 AM
Strides Pharma Science gains 5% on USFDA nod for skin ointment
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment is approximately $15 million.
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • Jun 2 6:28 AM
Strides Pharma gets USFDA nod for generic ointment to treat skin conditions
The approval is granted to the company's step-down wholly owned subsidiary, Strides Pharma Global, Singapore, by the United States Food and Drug Administration (USFDA) for triamcinolone acetonide ointment USP, 0.05 per cent, Strides Pharma Science said in a regulatory filing.
Moneycontrol
Like
Reply
T
Trade With Aryan @tradewithoutemot...
Reputation: 10,139 • Jun 2 4:33 AM
#STAR
STAR GOT USFDA OK FOR TRIAMCINOLONE ACETONIDE
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • May 25 3:28 AM
Buy Strides Pharma Science; target of Rs 421: ICICI Securities
ICICI Securities is bullish on Strides Pharma Science has recommended buy rating on the stock with a target price of Rs 421 in its research report dated May 21, 2020.
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • May 21 2:53 AM
Strides Pharma Consolidated March 2020 Net Sales at Rs 618.64 crore, up 0.4% Y-o-Y
Moneycontrol
Like
Reply
N
Nifty50Positional @boindextrader
Reputation: 1,239 • May 20 8:58 AM
Type
Buy
Instrument
STAR
Entry Price
₹422
Price@Trade
₹422
Target Price
₹480
Stop Price
₹410
Valid Till
Jun 19, 2020 3:20 AM
Margin
₹105,500 approx for 250 Qty
Status
Stoploss Hit
Exit Price
₹406.5
Net P&L
-₹3,875 (-3.67%)
#STAR
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
•
May 21 2:46 AM
Update
Stoploss Hit
Exit Price
₹406.5
T
Trading Calls @tradingcalls
Reputation: -13,918 • May 20 8:31 AM
Type
Buy
Instrument
STAR
Entry Price
₹421.3
Price@Trade
₹421.3
Target Price
₹480
Stop Price
₹380
Valid Till
May 21, 2020 3:20 AM
Margin
₹126,390 approx for 300 Qty
Status
Exited
Exit Price
₹435.85
Net P&L
+₹4,365 (+3.45%)
#STAR
Like
Reply (1)
Latest replies
Trading Calls @tradingcalls
•
May 21 2:52 AM
Update
Exited
Exit Price
₹435.85
Net P&L
+₹4,365 (+3.45%)
T
Trading Freaks95 Official @Tradingfreaks
Reputation: 5,083 • May 19 3:33 AM
Type
Buy
Instrument
STAR
Entry Price
₹415.5
Price@Trade
₹412.9
Target Price
₹430
Stop Price
₹408
Valid Till
May 27, 2020 3:20 AM
Margin
₹415,500 approx for 1000 Qty
Status
Exited
Exit Price
₹423.1
Net P&L
+₹7,600 (+1.83%)
#STAR
1
Reply (2)
Latest replies
TrackerBot @trackerbot
•
May 19 3:40 AM
Update
Trade Entered
Entry Price
₹415.5
Trading Freaks95 Official @Tradingfreaks
•
May 19 3:46 AM
Update
Exited
Exit Price
₹423.1
Net P&L
+₹7,600 (+1.83%)
S
Sandeep Pai @sandeeppai
Reputation: -694 • May 8 4:44 AM
STAR - chart - 773838
STAR - Shorted @ 431.9 and covered @ 423.9
RR - 1:2
#STAR #VolumeProfile #Intraday
#STAR
Like
Reply (1)
Latest replies
Sandeep Pai @sandeeppai
•
May 8 4:46 AM
STAR - 773845
#OrderDetails
T
Trade With Aryan @tradewithoutemot...
Reputation: 10,139 • Apr 30 4:32 AM
STAR
Type
Sell
Instrument
STAR
Entry Price
₹468.5
Price@Trade
₹468.6
Target Price
₹418.85
Stop Price
₹494
Valid Till
Apr 30, 2020 3:20 AM
Margin
₹99,790.5 approx for 213 Qty
Status
Validity Over
Exit Price
₹437.95
Net P&L
+₹6,507.15 (+6.52%)
#STAR
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
•
Apr 30 4:33 AM
Update
Trade Entered
Entry Price
₹468.5
TrackerBot @trackerbot
•
Apr 30 8:50 AM
Update
Validity Over
Exit Price
₹437.95
Net P&L
+₹6,507.15 (+6.52%)
S
Sridhar Balakrishnan @sridharbalakrishnan
Reputation: 32,634 • Apr 30 1:41 AM
Bangalore pharma company begins export of drug used to treat Covid-19 infection
Strides Pharma claimed to be the first Indian company to develop and commercially launch Favipiravir tablets for the global markets.The drug has shown to reduce the duration of Covid-19 and improved lung conditions in patients, Strides said.
Livemint
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • Apr 29 4:08 AM
Strides Pharma to export antiviral tablets for COVID-19, share price rises 11%
The company has developed Favipiravir tablets in 400mg and 200mg strengths for convenient dosage administration.
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 3,757 • Apr 20 6:23 AM
Strides receives USFDA approval for Flucytosine Capsules
The product is a generic version of Ancobon Capsules, 250 mg and 500 mg, of Bausch Health US, LLC, the Bengaluru- headquartered pharmaceutical company said in a statement.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
Join FrontPage

  • STAR - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization4,223.63
    Enterprise Value4,851.82
    Price to Earnings6.74
    Price to Book Value1.3
    Return on Capital Employed0.26
    Return on Equity0.28
    Face Value10
    Dividend YieldNA

  • STAR - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    17-Mar-20Geojit Financial ServicesHold357
    11-Dec-19Motilal OswalBuy440
    5-Jul-19ICICIdirect.comBuy472
    15-May-19Geojit Financial ServicesReduce401
    14-May-19HDFC SecuritiesBuy570
    STAR Brokerage Price Target

  • STAR Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 7413.95414.5407.55410.35
    Jul 6415.95415.95410412.4
    Jul 3416.65425.25410413.45
    Jul 2411.2416407.2412.9
    Jul 1410.2417.6404.2409.5

  • STAR Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹413.51
    30 Day Moving Average₹411.52
    50 Day Moving Average₹413.5
    100 Day Moving Average₹408.77
    200 Day Moving Average₹392.99

  • STAR - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,4702,109.8-0.3
    Operating Profit164186.99-0.12
    Profit Before Tax899123.96.26
    Net Income892108.547.22

  • STAR - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds3,2573,1620.03
    Total Liabilities1,4061,1690.2
    Total Assets4,6634,3310.08

  • STAR - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity66411.74-0.84
    Cash from Investing Activity433-882.82-1.49
    Cash from Financing Activity-707-67.249.51
    Net Cash Flow-208-538.32-0.61

  • STAR - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.210.02
    Return on Equity0.280.03
    Return on Capital Employed0.260.05

  • STAR - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.58
    3 Year CAGR Growth in Operating Profit0.44
    3 Year CAGR Growth in EBIDTA0.41
    3 Year CAGR Growth in Net Income0.68
    3 Yr CAGR Growth - Diluted EPS0.12

  • STAR - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.06
    5 Year CAGR Growth in Operating Profit4.28
    5 Year CAGR Growth in EBIDTA6.06
    5 Year CAGR Growth in Net Income14.93
    3 Yr CAGR Growth - Diluted EPS9.47

  • STAR - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 19 11:26 AM
    China to revamp benchmark equity index, STAR as pursues growth
    The Economic Times
    NewsBot
    Jun 2 7:23 AM
    Strides Pharma Science gains 5% on USFDA nod for skin ointment
    Moneycontrol
    NewsBot
    Jun 2 6:28 AM
    Strides Pharma gets USFDA nod for generic ointment to treat skin conditions
    Moneycontrol
    NewsBot
    May 25 3:28 AM
    Buy Strides Pharma Science; target of Rs 421: ICICI Securities
    Moneycontrol
    NewsBot
    May 21 2:53 AM
    Strides Pharma Consolidated March 2020 Net Sales at Rs 618.64 crore, up 0.4% Y-o-Y
    Moneycontrol
    NewsBot
    Apr 29 4:08 AM
    Strides Pharma to export antiviral tablets for COVID-19, share price rises 11%
    Moneycontrol
    NewsBot
    Apr 20 6:23 AM
    Strides receives USFDA approval for Flucytosine Capsules
    Moneycontrol
    NewsBot
    Apr 14 9:53 AM
    Four Indian drug makers' manufacturing plants get USFDA clearance, says report
    Moneycontrol
    NewsBot
    Apr 12 6:33 AM
    USFDA asks companies to remove ranitidine products; will Indian regulator review its stand?
    Moneycontrol
    NewsBot
    Apr 3 9:23 AM
    JB Chemicals, Solara Active, Strides tank 6-10% as USFDA requests withdrawal of Ranitidine
    Moneycontrol

  • STAR - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
Privacy•Terms•••
FrontPage © 2020